LDN193189
LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].
Product Specifications
CAS Number
[1062368-24-4]
Product Name Alternative
DM-3189
UNSPSC
12352005
Target
Organoid; TGF-β Receptor
Type
Reference compound
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LDN193189.html
Purity
99.48
Solubility
DMSO : 12.5 mg/mL (ultrasonic; adjust pH to 4 with HCl) |H2O : < 0.1 mg/mL|H2O : 5 mg/mL (ultrasonic; warming; adjust pH to 2 with 1 M HCL; heat to 60°C)
Smiles
C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16
Molecular Formula
C25H22N6
Molecular Weight
406.49
References & Citations
[1]Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14 (12), 1363-1369.|[2]Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290 (6) :3390-404.|[3]Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ALK2; ALK3
Citation 01
Adv Sci (Weinh) . 2024 Mar;11 (10) :e2308072.|Adv Sci (Weinh) . 2025 Jun 24:e02774.|Adv Sci (Weinh) . 2025 Nov 7:e12325.|Antioxid Redox Signal. 2025 Jul 25.|Biochim Biophys Acta Gen Subj. 2022 Jan;1866 (1) :130046.|Biomaterials. 2020 May;240:119849.|Biomedicines. 2022 Apr 18;10 (4) :928. |bioRxiv. 2024 Aug 6:2024.08.05.606734.|bioRxiv. 2024 Jul 11:2024.07.08.602611.|bioRxiv. 2024 Mar 13.|bioRxiv. 2024 Mar 25:2024.03.21.585753.|bioRxiv. 2024 Nov 4:2024.10.08.617155.|bioRxiv. 2024 November 15.|bioRxiv. 2024 November 28.|bioRxiv. 2025 April 14.|bioRxiv. 2025 Aug 8:2025.08.08.669417.|bioRxiv. 2025 February 21.|bioRxiv. 2025 March 15.|bioRxiv. 2025 Oct 11.|Cancer Metab. 2023 Jul 13;11 (1) :9.|Cardiovasc Toxicol. 2019 Jun;19 (3) :264-275.|Cell Commun Signal. 2024 May 30;22 (1) :300.|Cell Regen. 2025 May 16;14 (1) :18.|Cell Rep Methods. 2024 May 8:100777.|Cell Rep. 2023 Dec 5;42 (12) :113541.|Cell Signal. 2025 Sep 8:136:112116.|Cell Transplant. 2024 Jan-Dec:33:9636897241288932.|Dev Growth Differ. 2025 Apr;67 (3) :149-164.|Elife. 2025 Aug 28:14:RP104774.|EMBO Rep. 2023 Sep 6;24 (9) :e56454.|Eur Respir J. 2022 Jul 7;60 (1) :2100327.|Exp Ther Med. 2019 Apr;17 (4) :2648-2656. |Free Radic Biol Med. 2024 Dec 9:227:296-311.|Front Cell Dev Biol. 2021 May 13:9:673231.|Front Mol Biosci. 2021 Apr 26:8:663987.|Front Mol Biosci. 2021; 8: 663987.|Int J Mol Sci. 2022 Nov 27;23 (23) :14831.|Int J Mol Sci. 2024 Apr 9, 25 (8), 4138.|Int J Ophthalmol. 2022 May 18;15 (5) :711-720.|Int J Stem Cells. 2023 May 30;16 (2) :156-167.|iScience. 2019 Sep 27;19:1248-1259.|iScience. 2022 Dec 26;26 (1) :105898.|iScience. 2024 Feb 5;27 (3) :109111.|J Biomed Mater Res A. 2025 Oct;113 (10) :e38001.|J Hazard Mater. 2024 Mar 5:465:133028.|J Recept Signal Transduct Res. 2017 Oct;37 (5) :515-521.|Mar Drugs. 2022 Nov 14;20 (11) :715.|Mol Cell. 2022 Aug 4;82 (15) :2779-2796.e10.|Nucleic Acids Res. 2025 Oct 14;53 (19) :gkaf995.|Oxid Med Cell Longev. 2020 Jun 8;2020:4175613.|Patent. US20210346386A1.|Patent. US20240247230A1.|Pigment Cell Melanoma Res. 2024 Jan;37 (1) :21-35.|Res Sq. 2024 Nov 14.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2023 May 17.|Sci Rep. 2022 Mar 18;12 (1) :4740.|Sci Rep. 2022 Mar 25;12 (1) :5221.|STAR Protoc. 2024 Nov 27;5 (4) :103466.|Stem Cell Res Ther. 2022 Aug 19;13 (1) :424.|Stem Cell Res Ther. 2022 Sep 2;13 (1) :436.|Stem Cell Res Ther. 2023 Jan 5;14 (1) :1.|Stem Cell Res Ther. 2024 Dec 18;15 (1) :478.|Stem Cell Res Ther. 2025 May 13;16 (1) :239.|Stem Cells Int. 2022 Apr 28;2022:1560943.|Stem Cells Int. 2022 Dec 22:2022:1278921.|Stem Cells. 2023 Jun 15;41 (6) :603-616.|Transl Oncol. 2019 Dec 19;13 (2) :125-134|bioRxiv. 2024 July 03.|Cancer Lett. 2020 Jan 28;469:390-398.|Cell Rep. 2017 Aug 29;20 (9) :2227-2237. |Cell Rep. 2017 Aug 29;20 (9) :2227-2237. |Curr Protoc Cell Biol. 2018 Dec;81 (1) :e62.|Diabetes. 2020 Apr;69 (4) :634-646.|EMBO Rep. 2023 Sep 6;24 (9) :e56454.|Harvard Medical School LINCS LIBRARY|Nature. 2022 May;605 (7909) :325-331.|Patent. US20180263995A1.|Prostate. 2021 Dec;81 (16) :1435-1449.|Sci Adv. 2025 Nov 28;11 (48) :eady7682.|Stem Cell Res Ther. 2021 Jun 11;12 (1) :345.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6177852-01 0.1 mL
DEAF1 (Deformed Epidermal Autoregulatory Factor 1 (Drosophila), NUDR, SPN, ZMYND5) (FITC)
Ask
View Details 
MBS6177852-02 5x 0.1 mL
DEAF1 (Deformed Epidermal Autoregulatory Factor 1 (Drosophila), NUDR, SPN, ZMYND5) (FITC)
Ask
View Details 